R T Shuman1, R B Rothenberger, C S Campbell
1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Researchers designed novel tripeptide aldehydes that potently inhibit thrombin, a key enzyme in blood clotting. These selective thrombin inhibitors show promise as pharmacological tools and potential therapeutic agents for antithrombotic applications.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: